Why were Jennifer Stevens’ TriSalus (TLSI) share sales executed?

The filing states the shares were sold to satisfy tax withholding obligations related to vesting restricted stock units. It explicitly notes these transactions do not represent discretionary sales, indicating they were mechanical for tax compliance rather than active trading decisions.

Over what dates did the TriSalus (TLSI) insider share sales occur?

The reported transactions took place on March 11, March 12, and March 16. Each date involved a separate open-market sale, all linked by the company to tax withholding needs arising from restricted stock unit vesting.

TriSalus Life Sciences (TLSI) CRO sells shares for taxes

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

TriSalus Life Sciences Chief Regulatory Officer Jennifer Stevens reported routine share sales tied to tax withholding. She sold a total of 3,530 shares of common stock in open-market transactions between March 11 and March 16 at prices around $4.09–$4.13 per share.

According to the disclosure, the shares were sold solely to satisfy tax obligations from vesting restricted stock units and do not represent discretionary sales. After these transactions, she continues to hold 124,110 TriSalus shares directly.

Insider Trade Summary

Net Seller: 3,530 shares

Net Sell 3 txns

Insider Stevens Jennifer

Role Chief Regulatory Officer

Sold 3,530 shs ($15K)

Type	Security	Shares	Price	Value
Sale	Common Stock	774	$4.12	$3K
Sale	Common Stock	1,552	$4.09	$6K
Sale	Common Stock	1,204	$4.13	$5K

Holdings After Transaction: Common Stock — 124,110 shares (Direct)

Footnotes (1)

F1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/20/2026 - 04:25 PM

FAQ

What did TriSalus (TLSI) executive Jennifer Stevens report in this Form 4?

Jennifer Stevens reported selling 3,530 TriSalus shares in several March transactions. The sales were made to cover tax withholding required upon the vesting of restricted stock units, rather than as discretionary portfolio decisions.

How many TriSalus (TLSI) shares did Jennifer Stevens sell and at what prices?

She sold 3,530 common shares in total across three transactions. Reported sale prices ranged from about $4.09 to $4.13 per share, reflecting open-market executions around a consistent trading level across the disclosed dates.

How many TriSalus (TLSI) shares does Jennifer Stevens hold after these transactions?

Following the reported March sales, Jennifer Stevens directly holds 124,110 shares of TriSalus common stock. This post-transaction balance shows that the tax-related sales reduced, but did not significantly deplete, her overall equity position in the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stevens Jennifer

(Last)

(First)

(Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER

COLORADO

80031

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Regulatory Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/11/2026		S		1,204⁽¹⁾	D	$4.13	126,436	D
Common Stock	03/12/2026		S		1,552⁽¹⁾	D	$4.09	124,884	D
Common Stock	03/16/2026		S		774⁽¹⁾	D	$4.12	124,110	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR